Important Deadline Approaches for Regeneron Pharmaceuticals, Inc. Shareholders In Securities Class Action
The Gross Law Firm has officially notified the shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about an impending deadline regarding a securities class action lawsuit. This notice is significant for investors who purchased shares during the defined class period, which spans from August 1, 2025, to May 15, 2026.
During this timeframe, Regeneron allegedly provided misleading information to its investors while falsely representing its Phase III clinical trial results related to the Fianlimab-Libtayo study. According to the complaint, the company communicated excessively optimistic projections while concealing fundamental flaws in the study's design. Crucially, it has been reported that the assumptions guiding the clinical trial were fundamentally flawed. This led some analysts to question the trial's ability to achieve statistical significance, even in the absence of an unexpectedly strong performance from the control group.
The situation worsened significantly for the company on April 29, 2026, when Regeneron addressed shareholders during its first-quarter earnings call. It was revealed that the Phase III study had been modified to increase the pool of patients suitable for evaluating progression-free survival. This announcement resulted in a notable drop in the company’s stock price, plunging from $731.77 per share at market close on April 28, 2026, to $686.36 the very next day, marking a steep decline of approximately 6.2%.
May 15, 2026, proved to be another tumultuous day. Regeneron disclosed in a press release that its Phase 3 trial of Fianlimab did not reach statistical significance regarding the primary endpoint, which was the improvement in progression-free survival. Following this information, Regeneron's stock took another hit, dropping about 9.8% from a closing price of $698.25 on May 15 to $629.68 by May 18.
The deadline for interested shareholders to register for this class action is September 14, 2026. Investors are encouraged not to delay in submitting their information to ensure their involvement in the potential recovery process. Those who register will gain access to portfolio monitoring, providing updates around the case’s progression.
The Gross Law Firm, known for its commitment to protecting investors' rights and holding companies accountable for harmful practices, is spearheading this initiative. The firm is recognized nationally for its advocacy in class action lawsuits, focusing on corporate malfeasance that leads to financial losses for consumers and investors alike. Importantly, potential participants do not have to take on the risk of appointing a lead plaintiff to partake in any potential recovery.
For further information regarding the registration process or legal representation, shareholders can visit the firm’s designated webpage at Gross Law Firm's Registration Portal. Investors need to act promptly given the comprehensive timeline of this case and the repercussions that can follow improper disclosures.
During this timeframe, Regeneron allegedly provided misleading information to its investors while falsely representing its Phase III clinical trial results related to the Fianlimab-Libtayo study. According to the complaint, the company communicated excessively optimistic projections while concealing fundamental flaws in the study's design. Crucially, it has been reported that the assumptions guiding the clinical trial were fundamentally flawed. This led some analysts to question the trial's ability to achieve statistical significance, even in the absence of an unexpectedly strong performance from the control group.
The situation worsened significantly for the company on April 29, 2026, when Regeneron addressed shareholders during its first-quarter earnings call. It was revealed that the Phase III study had been modified to increase the pool of patients suitable for evaluating progression-free survival. This announcement resulted in a notable drop in the company’s stock price, plunging from $731.77 per share at market close on April 28, 2026, to $686.36 the very next day, marking a steep decline of approximately 6.2%.
May 15, 2026, proved to be another tumultuous day. Regeneron disclosed in a press release that its Phase 3 trial of Fianlimab did not reach statistical significance regarding the primary endpoint, which was the improvement in progression-free survival. Following this information, Regeneron's stock took another hit, dropping about 9.8% from a closing price of $698.25 on May 15 to $629.68 by May 18.
The deadline for interested shareholders to register for this class action is September 14, 2026. Investors are encouraged not to delay in submitting their information to ensure their involvement in the potential recovery process. Those who register will gain access to portfolio monitoring, providing updates around the case’s progression.
The Gross Law Firm, known for its commitment to protecting investors' rights and holding companies accountable for harmful practices, is spearheading this initiative. The firm is recognized nationally for its advocacy in class action lawsuits, focusing on corporate malfeasance that leads to financial losses for consumers and investors alike. Importantly, potential participants do not have to take on the risk of appointing a lead plaintiff to partake in any potential recovery.
For further information regarding the registration process or legal representation, shareholders can visit the firm’s designated webpage at Gross Law Firm's Registration Portal. Investors need to act promptly given the comprehensive timeline of this case and the repercussions that can follow improper disclosures.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.